International Stem Cell Corp. (ISCO)

[236T568]

regarding the low alleged market cap that you are claiming, you forgot to look at the massive dilution caused by the 5 different classes of convertible preferred stock outstanding, the warrants outstanding and the options outstanding

The extension study to monitor and evaluate patients every 6 months for 5 years is critical. I am glad they noted this. A 1 or 2 year evaluation is insufficient. I still do not understand the market cap for this company. There are many many many more small developmental companies out there that have less potential that are at least in the 40 to 80 million dollar capitalization range. ISCO is beyond simply developmental with profitable subsidiaries generating usable cash and clinical stage progress. Comparatively, it is my opinion this should be at least a 100 million cap at the moment and even with say an 20 million outstanding share potential, that is over $5/share. I would like to see the information on the latest efficacy report. They need to see improvement during the 'off' periods.